Slide 1: Exchange filing cover letter for revised investor presentation
<$siocon Bio ..un Limite-d 20th KM Hosur Road Electronics City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN: L24234KA1978PLC003417 www.biocon.com September 11, 2019 To To The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Serv
Slide 2: Biocon Limited Investor Presentation September 2019
Biocon Limited BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM Investor Presentation September 2019
Slide 3: Safe Harbor
Safe Harbor Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.
Slide 4: Agenda
Agenda Our Journey Financial Highlights • Small Molecules Our Business • Biologics • Branded Formulations • Research Services - Syngene Five Year Financials Enduring 3 Edge
Slide 5: Biocon: Asia’s Leading Biopharma Company
Biocon: Asia’s Leading Biopharma Company Our Vision To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe Our Mission To be an integrated Biotech enterprise of global distinction Our Values Integrity & Ethical
Slide 6: Committed to Affordable Access
Committed to Affordable Access Aiming to develop products that can potentially benefit a billion patients Enduring 5 Edge
Slide 7: The Biocon Journey: A Continuous Evolution
The Biocon Journey: A Continuous Evolution 1978-1999 2000-2004 2005-2009 2010-2015 2016 and beyond Focused on Transforming Building the global Poised for Global An Enzymes into a Base Business development and Impact with Company Biopharma and Expertise in strategic global Biosimilars Company Biologi
Slide 8: Key Innovations: Making a Difference
Key Innovations: Making a Difference Ogivri™, first biosimilar Trastuzumab approved by US FDA Launches Second Novel Ogivri™, Biologic (Insulin Glargine biosimilar prefilled disposable Launches KRABEVA®, Trastuzumab in pen) biosimilar Bevacizumab First Novel EU, Australia in India Biologic Launches L
Slide 9: Financial Highlights
Financial Highlights Enduring Edge
Slide 10: Financial Summary
Financial Summary All Figures in ₹ Million except % Growth Particulars Q1 FY20 Q1 FY19 Growth FY19 FY18 (%) Revenue 14,900 11,926 25% 56,588 43,359 31% EBITDA 4,616 3,066 51% 15,381 10,353 49% Net Profit# 2,229 1,197 86% 7,291 3,724 96% R&D Expenses in 787 442 78% 2,899 2,158 34% P&L Gross R&D Spend
Slide 11: Revenue Highlights
Revenue Highlights All Figures in ₹ Million except % Particulars by segment Q1 FY20 Q1 FY19 Growth FY19 FY18 Growth - Small Molecules 4,796 4,001 20% 17,728 15,077 18% - Biologics 4,896 2,497 96% 15,169 7,702 97% - Branded Formulations 1,334 1,473 -9% 6,654 6,115 7% - Syngene (Research Services) 4,2
Slide 12: Key Financial Metrics – Evolution over last 5 quarters
Key Financial Metrics – Evolution over last 5 quarters All Figures in ₹ Million except % FY 2019 FY 2020 Particulars Q1 Q2 Q3 Q4 FY19 Q1 SEGMENT REVENUE a. Small Molecules 4,001 4,319 4,689 4,719 17,728 4,796 b. Biologics 2,497 3,675 4,486 4,511 15,169 4,896 c. Branded Formulations 1,473 1,639 2,122
Slide 13: Our Business
Our Business - aS Enduring $ Biocon | Edge gouges Wwe : tid
Slide 14: Business Segments
Business Segments Biologics Novel Biologics & Biosimilars Innovation in biologics development including novel molecules & biosimilars Small Molecules Research Services Syngene Differentiated APIs CRO offering integrated service platform & Generic Formulations for novel molecule drug discovery & deve
Slide 15: Small Molecule: APIs & Generic Formulations
Small Molecule : APIs & Generic Formulations Differentiated APIs Current Constituents Portfolio Product Portfolio leverages core Simvastatin, Pravastatin, Atorvastatin, fermentation technology strengths Statins Rosuvastatin, & Fluvastatin. Among world’s largest manufacturers of Tacrolimus, Sirolimus
Slide 16: Biologics: Biosimilars & Novel Biologics
Biologics: Biosimilars & Novel Biologics Novel Biologics Biosimilars Positioned among early Creating market leadership wave of entrants with in Innovation e.g., Insulin multiple biosimilars Tregopil, Itolizumab commercialized globally. 15+ years of experience is developing biologics. Pipeline includ
Slide 17: Strategic Partnership with Mylan for Biosimilars: Insulins & mAbs
Strategic Partnership with Mylan for Biosimilars: Insulins & mAbs Partnership leverages Biocon’s Strong Development & Manufacturing Capability and Mylan’s Regulatory & Commercial Excellence BIOCON MYLAN • Global-scale, complex biologics • Strength in Regulatory/ filings manufacturing capabilities st
Slide 18: Strategic Partnership with Sandoz for next generation Biosimilars
Strategic Partnership with Sandoz for next generation Biosimilars Broader Biocon Biologics participation in end to end development and commercialization with a global leader in biosimilars Portfolio addresses next wave of immunology and oncology biosimilars Market opportunity to open up by middle of
Slide 19: Status of Biocon Biologics Global Biosimilars Portfolio
Status of Biocon Biologics Global Biosimilars Portfolio* Therapeutic Area Molecule Status Oncology TRASTUZUMAB Launched in EU, Australia & Emerging Markets. Approved in U.S. & Canada. Oncology PEGFILGRASTIM Launched in the U.S. Approved in EU, Australia & Canada. Oncology BEVACIZUMAB Launched in Ind
Slide 20: Biocon Biologics Well Placed in Competitive Global Landscape (1)
Biocon Biologics Well Placed in Competitive Global Landscape (1) Molecule Biosimilar Development Pipeline$ Phase I Phase 3 Regulatory Submission Approved/ Marketed EMA FDA EMA FDA ADALIMUMAB DM Bio Coherus, Celltrion, Pfizer Pfizer Amgen, Samsung, Amgen, BI, Alvotech, Sandoz, Fresnius/ Sandoz, Samsu
Slide 21: Biocon Biologics Well Placed in Competitive Global Landscape (2)
Biocon Biologics Well Placed in Competitive Global Landscape (2) Molecule Biosimilar Insulin Development Pipeline$ Phase I Phase 3 Regulatory Submission Approved/ Marketed EMA FDA EMA FDA INSULIN GLARGINE Lannett/ HEC Gan & Lee/ Sandoz BIOCON BIOCON, Eli Lilly, Eli Lilly, Merck Merck (TA) INSULIN AS
Slide 22: Biosimilars Manufacturing: Building Global Scale
Biosimilars Manufacturing: Building Global Scale Global Scale Manufacturing Capabilities in India State-of-the-art manufacturing facilities – mammalian & microbial Facilities conform to most stringent cGMP guidelines - Inspected by EMA, USFDA, Health Canada, ANVISA, COFEPRIS, PMDA, TGA etc. Second f
Slide 23: Biocon Biologics: The Four Pillars
Biocon Biologics: Transforming Healthcare, Transforming Lives Vision: “Most Inspiring Global Leader in Biologics” delivering affordable access to innovative and inclusive healthcare solutions, transforming patient lives. Implement strategic initiatives going beyond the product in our aspiration to r
Slide 24: Branded Formulations: Now aligned with Biologics Growth Strategy
Branded Formulations: Now aligned with Biologics Growth Strategy Specialty business with regional ambitions; strong value builder for Biocon. Biologics-led specialty products focused on chronic therapy areas. Comprehensive offering of products, patient and physician support programs INDIA UAE India’
Slide 25: Novel Molecules - Pipeline & Therapeutic Area Focus
Novel Molecules - Pipeline & Therapeutic Area Focus Insulin Tregopil (In-house program) First-in-Class Oral, Prandial Insulin India Phase II/III in DIABETES • Liver specific- portal delivery, Weight neutral T2D ongoing • Pivotal Phase II/III clinical study in T2DM patients in India ongoing • JDRF su
Slide 26: Research Services Business: Syngene
Research Services Business: Syngene One of leading India based CROs, a global high growth CRO company End-to-end discovery, development and manufacturing capabilities with focus on novel molecular entities Offers an integrated drug discovery, development and manufacturing platform for both small and
Slide 27: Biocon: Group Structure
Biocon: Group Structure Research Biocon Limited, Biosimilars Services India 70.24% 100% 49% 100% 100% 98% 100% Biocon Syngene Neo Biocon Biocon Biologics Biocon Biocon FZ Pharma Biocon SA International FZ LLC, India Limited, Research LLC, UAE Limited, Switzerland Limited, India UAE India Limited Ind
Slide 28: Investor Relations contact
Investor Relations contact: Saurabh Paliwal Tel : +91 80 6775 2040 Email: investor.relations@biocon.com For further information, please visit www.biocon.com 27